Upgrade to SI Premium - Free Trial

Form 3 CASI Pharmaceuticals, For: Mar 18 Filed by: Huang Hai

April 7, 2026 4:36 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Huang Hai
(Last) (First) (Middle)
1701, CHINA CENTRAL OFFICE TOWER 1
NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT
(Street)
BEIJING 100025
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Global Chief Commercial Ofcr
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) (1) 01/29/2034 Ordinary Share 75,000 6.61 D
Option (right to buy) 01/29/2027 01/29/2034 Ordinary Share 37,500 6.61 D
Option (right to buy) 01/29/2028 01/29/2034 Ordinary Share 37,500 6.61 D
Option (right to buy) (1) 06/18/2034 Ordinary Share 7,500 2.67 D
Option (right to buy) 06/18/2026 06/18/2034 Ordinary Share 7,500 2.67 D
Option (right to buy) 06/18/2027 06/18/2034 Ordinary Share 7,500 2.67 D
Option (right to buy) 06/18/2028 06/18/2034 Ordinary Share 7,500 2.67 D
Option (right to buy) (2) 01/29/2034 Ordinary Share 100,000 6.61 D
Explanation of Responses:
1. The options are fully vested and exercisable as of the date of this form.
2. Performance based options exercisable upon achievement of performance target.
/s/ Hai Huang 04/07/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings